肝细胞肝癌组织c-Met、Fascin及CD44表达与临床病理特征及预后的相关性  

Associations of c-Met,Fascin and CD44 with clinical pathological features and prognosis of patients with hepatocellular carcinoma

作　　者：朱琳[1] 陈莉[2] 肖锋[1] 张海燕 顾春燕[1] ZHU Lin;CHEN Li;XIAO Feng;ZHANG Hai-yan;GU Chun-yan(Department of Pathology,Nantong 3rd People’s Hospital,Nantong Third Hospital Affiliated Nantong University,Nantong 226000,Jiangsu,China;Department of Pathology,Nantong University Medical School,Nantong 226001,Jiangsu,China)

机构地区：[1]南通市第三人民医院病理科,南通大学附属南通第三医院,南通226000 [2]南通大学医学院病理系,南通226001

出　　处：《中国临床医学》2022年第5期745-752,共8页Chinese Journal of Clinical Medicine

基　　金：南通市市级科技计划项目(MSZ21037);南通市卫生健康委员会科研课题专项(MB2021058,MA2019010,MB2020031).

摘　　要：目的探讨肝细胞肝癌(hepatocelluar carcinoma,HCC)中c-Met、Fascin及CD44的表达与临床病理特征及预后之间的关系。方法从癌症基因组图谱(the cancer genome atlas,TCGA)数据库下载HCC中c-Met、Fascin及CD44的RNA SEqV2资料,比较50例HCC组织和对应癌旁肝组织中三者的表达。采用蛋白质印迹法分别检测6例新鲜HCC及对应癌旁肝组织中c-Met、Fascin及CD44的蛋白表达。通过免疫组织化学法(immunohistochemistry,IHC)检测186例HCC患者中HCC组织及癌旁组织c-Met、Fascin及CD44蛋白的表达,分析三者与临床病理特征及预后的关系。结果TCGA显示,HCC组织中c-Met、Fascin及CD44的mRNA表达较癌旁肝组织升高(P<0.01)。蛋白质印迹显示,新鲜HCC组织中c-Met、Fascin及CD44蛋白表达水平均高于癌旁肝组织(P<0.05)。IHC显示,186例HCC患者癌组织及癌旁组织中,c-Met蛋白表达阳性率分别为60.2%(112/186)和32.8%(61/186),Fascin蛋白表达阳性率分别为56.5%(105/186)和24.7%(46/186),CD44蛋白表达阳性率分别为73.1%(136/186)和50.5%(94/186),3种蛋白在HCC组织中的表达均高于癌旁组织(P<0.01)。c-Met、Fascin及CD44蛋白在脉管侵犯、低分化及术后复发患者癌组织表达中均增加(P<0.05)。Spearman相关性分析显示,c-Met与Fascin的表达正相关(r=0.3495,P<0.001)。Kaplan-Meier生存分析及多因素Cox回归分析显示,c-Met、Fascin及CD44表达是影响HCC患者生存的危险因素(P<0.05)。结论c-Met、Fascin及CD44的mRNA和蛋白表达水平在HCC组织中均升高,在脉管侵犯、肿瘤低分化及复发患者HCC组织中水平更高,且为HCC患者生存的独立危险因素。Objective To explore the association of c-Met, Fascin and CD44 with the clinical pathological fetures and prognosis of patients with hepatocellular carcinoma(HCC). Methods The RNA SEqV2 data of c-Met, Fascin and CD44 in HCC from the cancer genome atlas(TCGA) were downloaded(n=50). The mRNA levels of c-Met, Fascin and CD44 between cancer and paracancer tissues were compared. Western blotting was used to detect the expression levels of c-Met, Fascin and CD44 proteins in 6cases of cancer and the matched paracancer liver tissues. The expression levels of c-Met, Fascin and CD44 proteins were examined in cancer and paracancer liver tissues from 186 patients by immunohistochemistry(IHC). The associations of c-Met, Fascin and CD44with clinical pathological factors and prognosis of patients were analyzed. Results The data from TCGA showed that the mRNA levels of c-Met, Fascin and CD44 were signiflcantly higher in cancer tissues than those in the paracancer tissues(P<0.01). Western blotting results showed that the protein levels of c-Met, Fascin and CD44 in fresh cancer tissues were signiflcantly higher than those in the paracancer tissues(P<0. 05). IHC results showed the c-Met expressed in 60.2%(112/186) of cancer tissues and 32.8%(61/186)of paracancer tissues, Fascin expressed in 56.5%(105/186) of cancer tissues and 24.7%(46/186) of paracancer tissues, and CD44expressed in 73.1%(136/186) of cancer tissues and 50.5%(94/186) of paracancer tissues. The protein levels of c-Met, Fascin and CD44 in cancer tissues were higher than those in paracancer tissues(P<0.01). The expressions of c-Met,Fascin and CD44 proteins in patients with vascular invasion or poor differentiation tumor and in recurrence patients were higher(P<0.05). Spearman analysis showed that there was a positive correlation between c-Met and Fascin(r=0.349 5, P<0.001). Kaplan-Meier and multivariate Cox analysises all showed that higher levels of c-Met, Fascin and CD44 were risk factors for HCC patients survival(P<0.05).Conclusion c-Met, Fascin and CD44 expression

关 键 词：C-MET FASCIN CD44 肝细胞肝癌 脉管癌栓 复发 

分 类 号：R735.7[医药卫生—肿瘤]